ArticleRadiological physics and technology2026
The role of cone beam CT in personalization of bladder cancer radiotherapy.
Article in Radiological physics and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate discrepancies between planned, delivered and adapted doses to target and organs at risk (OARs) during bladder cancer radiotherapy, using deformable image registration from CT to CBCT in view of better treatment personalization. Twenty patients with a total of 165 CBCT images were analysed. Intensity modulated techniques (IMRT and VMAT) were simulated in the Monaco planning system. The initial plans were adapted to each CBCT using the Adapt to shape (ATS) function. A reduction in PTV66 and CTV66 coverage was observed upon calculation of treatment dose on CBCTcalc in comparison with plans on CT. The PTV66 coverage was 86.7% IMRT and 86.4% VMAT, respectively. Meanwhile, the optimized plans on CBCTopt provided PTV66 coverage of 97.1% IMRT and 96.4% VMAT, which was similar to the initial planning on CT (97.4% IMRT and 96.6% VMAT). Furthermore, CTV66 showed a coverage of 94.2% IMRT and 94.0% VMAT on CBCTcalc, in comparison to the values on CT (99.8% IMRT and 99.9% VMAT) and the values on CBCTopt (99.8% IMRT and 99.8% VMAT). For OARs, the rectum, bowel bag, and sigmoid exhibited higher values on CBCTcalc than on CT planning and CBCTopt. This study demonstrates that CBCT- guided adaptive radiotherapy enhances treatment precision and personalization in bladder cancer, improving target coverage and reducing radiation exposure to healthy tissues. Next to highlighting the importance of personalizing bladder cancer radiotherapy, the study substantiates that daily reoptimization with ATS constitutes an efficacious strategy in centers with limited resources.
Indexed as
Identifiers
41396417What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.